Fonseca Biosciences Launches XTORO® (finafloxacin otic suspension) 0.3% for Acute Otitis Externa
Fonseca Biosciences, a specialty pharmaceutical company commercializing clinically differentiated pharmaceutical products, today announced the launch of XTORO® (finafloxacin otic suspension), 0.3% for the treatment of acute otitis externa (AOE), commonly known as swimmer's ear, caused by susceptible strains of Pseudomonas aeruginosa and Staphylococcus aureus. The launch follows FDA approval of the Prior Approval Supplement (PAS) required for commercial manufacturing of XTORO, clearing the final regulatory hurdle to U.S. commercialization.
